Assay
Depot Inc. this week announced the launch of a virtual research
laboratory. Developed in partnership with AstraZeneca, the virtual
laboratory is a powerful vendor relationship management (VRM) system
that gives researchers easy access to a distributed network of thousands
of research service providers located inside and outside the company.
“By
connecting our internal and external science, the virtual laboratory
platform is creating a new approach for our scientists to run
experiments with an optimal balance of speed, quality, and cost. We look
forward to assessing how the virtual laboratory platform impacts and
accelerates productivity in the R&D pipeline”
“We
brought together features of today’s favorite consumer websites to
create a virtual laboratory that empowers scientists,” stated Kevin
Lustig, Assay Depot’s CEO. “A small group of talented scientists can now
run an entire drug discovery program, from concept to clinic, from a
laptop computer.”
The
private virtual laboratory (aka Research Exchange) enables researchers
to search for research services and vendors, communicate with experts,
purchase services, and rate and review services. In one simple and
intuitive interface, scientists identify experts, initiate research
collaborations, and track entire projects to completion.
Researchers
can access the virtual laboratory from anywhere they access the
Internet, including tablets and mobile devices. They can view their
colleagues’ ratings and reviews, view past transactions and determine at
a glance which vendors have current legal agreements.
“The
virtual drug discovery era has arrived,” said Chris Petersen, Assay
Depot’s CIO. “Enabling research scientists to access any service and any
expert in just a few mouse clicks can dramatically improve
productivity, reduce costs and promote innovation.”
A
private virtual laboratory enables complete transparency across global
research operations while retaining local control over research sourcing
decisions. It simplifies legal and compliance verification,
standardizes sourcing governance and serves as a versatile all-in-one
platform that benefits the entire chain of pharmaceutical stakeholders,
including discovery research, supply chain and consumer health.
“By
connecting our internal and external science, the virtual laboratory
platform is creating a new approach for our scientists to run
experiments with an optimal balance of speed, quality, and cost. We look
forward to assessing how the virtual laboratory platform impacts and
accelerates productivity in the R&D pipeline,” said Mike Snowden,
Vice President, Discovery Sciences, AstraZeneca.
Source: BusinessWire
Filed Under: Drug Discovery
